Research ArticleSystemic Lupus Erythematosus

High Systemic Type I Interferon Activity Is Associated With Active Class III/IV Lupus Nephritis

Taro Iwamoto, Jessica M. Dorschner, Shanmugapriya Selvaraj, Valeria Mezzano, Mark A. Jensen, Danielle Vsetecka, Shreyasee Amin, Ashima Makol, Thomas Osborn, Kevin Moder, Vaidehi R. Chowdhary, Peter Izmirly, H. Michael Belmont, Robert M. Clancy, Jill P. Buyon, Ming Wu, Cynthia A. Loomis and Timothy B. Niewold
The Journal of Rheumatology April 2022, 49 (4) 388-397; DOI: https://doi.org/10.3899/jrheum.210391

REFERENCES

  1. 1.↵
    1. Tsokos GC.
    Systemic lupus erythematosus. N Engl J Med 2011;365:2110-21.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Weckerle CE,
    2. Niewold TB.
    The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol 2011;40:42-9.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Izmirly PM,
    2. Wan I,
    3. Sahl S, et al.
    The incidence and prevalence of systemic lupus erythematosus in New York County (Manhattan), New York: the Manhattan Lupus Surveillance Program. Arthritis Rheumatol 2017;69:2006-17.
    OpenUrl
  4. 4.↵
    1. Hanly JG,
    2. O’Keeffe AG,
    3. Su L, et al.
    The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology 2016;55:252-62.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Costenbader KH,
    2. Desai A,
    3. Alarcón GS, et al.
    Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum 2011;63:1681-8.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Croca SC,
    2. Rodrigues T,
    3. Isenberg DA.
    Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology 2011;50:1424-30.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Crow MK,
    2. Olferiev M,
    3. Kirou KA.
    Targeting of type I interferon in systemic autoimmune diseases. Transl Res 2015;165:296-305.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Postal M,
    2. Vivaldo JF,
    3. Fernandez-Ruiz R,
    4. Paredes JL,
    5. Appenzeller S,
    6. Niewold TB.
    Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin Immunol 2020;67:87-94.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Blanco P,
    2. Palucka AK,
    3. Gill M,
    4. Pascual V,
    5. Banchereau J.
    Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001;294:1540-3.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Kiefer K,
    2. Oropallo MA,
    3. Cancro MP,
    4. Marshak-Rothstein A.
    Role of type I interferons in the activation of autoreactive B cells. Immunol Cell Biol 2012;90:498-504.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Lövgren T,
    2. Eloranta ML,
    3. Båve U,
    4. Alm GV,
    5. Rönnblom L.
    Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004; 50:1861-72.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Tian J,
    2. Avalos AM,
    3. Mao SY, et al.
    Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8:487-96.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Niewold TB,
    2. Hua J,
    3. Lehman TJ,
    4. Harley JB,
    5. Crow MK.
    High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007;8:492-502.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Niewold TB,
    2. Adler JE,
    3. Glenn SB,
    4. Lehman TJ,
    5. Harley JB,
    6. Crow MK.
    Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum 2008;58:2113-9.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Niewold TB,
    2. Kelly JA,
    3. Flesch MH,
    4. Espinoza LR,
    5. Harley JB,
    6. Crow MK.
    Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 2008;58:2481-7.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Salloum R,
    2. Franek BS,
    3. Kariuki SN, et al.
    Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum 2010;62:553-61.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Niewold TB,
    2. Kelly JA,
    3. Kariuki SN, et al.
    IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis 2012;71:463-8.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Kim T,
    2. Kanayama Y,
    3. Negoro N,
    4. Okamura M,
    5. Takeda T,
    6. Inoue T.
    Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987;70:562-9.
    OpenUrlPubMed
  19. 19.↵
    1. Bengtsson AA,
    2. Sturfelt G,
    3. Truedsson L, et al.
    Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-71.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Weckerle CE,
    2. Franek BS,
    3. Kelly JA, et al.
    Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum 2011;63:1044-53.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Baechler EC,
    2. Batliwalla FM,
    3. Karypis G, et al.
    Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610-5.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Kirou KA,
    2. Lee C,
    3. George S,
    4. Louca K,
    5. Peterson MG,
    6. Crow MK.
    Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005;52:1491-503.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Feng X,
    2. Wu H,
    3. Grossman JM, et al.
    Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2951-62.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Oke V,
    2. Gunnarsson I,
    3. Dorschner J, et al.
    High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther 2019;21:107.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Der E,
    2. Suryawanshi H,
    3. Morozov P, et al.
    Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol 2019;20:915-27.
    OpenUrlPubMed
  26. 26.↵
    1. Hochberg MC.
    Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Weening JJ,
    2. D’Agati VD,
    3. Schwartz MM, et al.
    The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-50.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Mina R,
    2. Abulaban K,
    3. Klein-Gitelman MS, et al.
    Validation of the lupus nephritis clinical indices in childhood-onset systemic lupus erythematosus. Arthritis Care Res 2016;68:195-202.
    OpenUrl
  29. 29.↵
    1. Hua J,
    2. Kirou K,
    3. Lee C,
    4. Crow MK.
    Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006;54:1906-16.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Sakairi T,
    2. Abe Y,
    3. Kajiyama H, et al.
    Conditionally immortalized human podocyte cell lines established from urine. Am J Physiol Renal Physiol 2010;298:F557-67.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Nakamura T,
    2. Ushiyama C,
    3. Suzuki S, et al.
    Urinary podocytes for the assessment of disease activity in lupus nephritis. Am J Med Sci 2000;320:112-6.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Wang Y,
    2. Yu F,
    3. Song D,
    4. Wang SX,
    5. Zhao MH.
    Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: a large cohort study from a single centre. Rheumatology 2014;53:1235-44.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Kim JM,
    2. Wu H,
    3. Green G, et al.
    CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 2003;300:1298-300.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Swiecki M,
    2. Colonna M.
    The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol 2015;15:471-85.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Bastian HM,
    2. Alarcón GS,
    3. Roseman JM, et al.
    Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria. Rheumatology 2007;46:683-9.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Bastian HM,
    2. Roseman JM,
    3. McGwin G Jr, et al.
    Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002;11:152-60.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Isenberg DA,
    2. Manson JJ,
    3. Ehrenstein MR,
    4. Rahman A.
    Fifty years of anti-ds DNA antibodies: are we approaching journey’s end? Rheumatology 2007;46:1052-6.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Psarras A,
    2. Alase A,
    3. Antanaviciute A, et al.
    Functionally impaired plasmacytoid dendritic cells and nonhaematopoietic sources of type I interferon characterize human autoimmunity. Nat Commun 2020;11:6149.
    OpenUrlPubMed
  39. 39.↵
    1. Morand EF,
    2. Furie R,
    3. Tanaka Y, et al.
    Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 2020;382:211-21.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Paredes JL,
    2. Niewold TB.
    Type I interferon antagonists in clinical development for lupus. Expert Opin Investig Drugs 2020; 29:1025-41.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

interferon signature gene
LUPUS NEPHRITIS
podocyte injury type I interferon

Keywords